Get the Stockscreener App
24.51
8.68%
-2.33
After Hours:
24.99
0.48
+1.96%
Alumis Inc stock is traded at $24.51, with a volume of 1.88M.
It is down -8.68% in the last 24 hours and up +148.08% over the past month.
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.
See More
Previous Close:
$26.84
Open:
$26.42
24h Volume:
1.88M
Relative Volume:
0.70
Market Cap:
$3.06B
Revenue:
-
Net Income/Loss:
$-238.77M
P/E Ratio:
-0.9143
EPS:
-26.808
Net Cash Flow:
$-216.62M
1W Performance:
-0.04%
1M Performance:
+148.08%
6M Performance:
+497.80%
1Y Performance:
+264.73%
1-Day Range:
$24.44
$26.63
1-Week Range:
$23.45
$28.29
52-Week Range:
$2.7601
$28.29
Alumis Inc Stock (ALMS) Company Profile
Name
Alumis Inc
Sector
Industry
Phone
650-231-6625
Address
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
24.51 | 3.35B | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-26 | Initiated | Chardan Capital Markets | Buy |
| Jul-25-25 | Initiated | Wells Fargo | Overweight |
| Jun-10-25 | Resumed | Guggenheim | Buy |
| Jan-30-25 | Initiated | Oppenheimer | Outperform |
| Oct-31-24 | Initiated | Robert W. Baird | Outperform |
| Oct-17-24 | Initiated | H.C. Wainwright | Buy |
| Jul-23-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-23-24 | Initiated | Guggenheim | Buy |
| Jul-23-24 | Initiated | Leerink Partners | Outperform |
| Jul-23-24 | Initiated | Morgan Stanley | Overweight |
View All
Alumis Inc Stock (ALMS) Latest News
Chardan Highlights Alumis’s (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Insider Monkey
Top Small Cap Stocks To Watch NowJanuary 6th - MarketBeat
10 New Stocks on the Rise - Insider Monkey
Alumis stock hits all-time high at 27.28 USD By Investing.com - Investing.com Canada
Alumis stock hits all-time high at 27.28 USD - Investing.com
Alumis (NASDAQ:ALMS) Trading Up 6.4%Should You Buy? - MarketBeat
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - AOL.com
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Alumis (NASDAQ:ALMS) Coverage Initiated by Analysts at Chardan Capital - MarketBeat
Alumis Inc. (ALMS) Stock Analysis: Exploring A 39% Upside In The Biotech Arena - DirectorsTalk Interviews
Alumis stock reaches all-time high at 25.25 USD By Investing.com - Investing.com Australia
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Chardan Capital initiates coverage on Alumis stock with Buy rating - Investing.com
Chardan Capital initiates coverage on Alumis stock with Buy rating By Investing.com - Investing.com India
Alumis (NASDAQ:ALMS) Hits New 12-Month HighWhat's Next? - MarketBeat
Profit Recap: Is now the right time to enter ASTCJuly 2025 WrapUp & Technical Confirmation Alerts - baoquankhu1.vn
Trading Recap: Is Alumis Inc gaining market shareJuly 2025 Market Mood & Growth Focused Entry Point Reports - baoquankhu1.vn
Aug Reactions: What is the long term forecast for XPLR Infrastructure LP Limited Partnership stock - baoquankhu1.vn
Alumis stock reaches all-time high at 25.25 USD - Investing.com
Aug Weekly: What’s Enterprise Products Partners L.P. Limited Partnership’s historical returnMarket Activity Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs - 24/7 Wall St.
Alumis (ALMS) Is Up 22.0% After Phase 3 Psoriasis Win And $300 Million Equity Raise - Yahoo Finance
HC Wainwright & Co. hikes Alumis Inc. (ALMS)’s price target to $40 from $20, reiterates buy rating - MSN
Alumis (ALMS) price target increased by 79.14% to 36.28 - MSN
An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million - AOL.com
Staar Surgical, Alumis, and more stocks see action from activist investors - MSN
Staar Surgical, Alumis, and More Stocks See Action From Activist Investors - Barron's
Russell 2000 Kicks Off 2026 Strong, Surging Over 7% Year-to-Date - Intellectia AI
14 Best Booming Stocks to Buy Right Now - Insider Monkey
HC Wainwright & Co. Hikes Alumis Inc. (ALMS)’s Price Target To $40 From $20, Reiterates Buy Rating - Insider Monkey
Why is ALMS stock rising today? - MSN
Alumis (ALMS) Is Up 35.8% After Psoriasis Data And $300M Raise Has The Bull Case Changed? - simplywall.st
Alumis (ALMS) stock jumps as insider filings show $17 buys — what investors are watching next - TechStock²
Why Alumis Inc. Stock Is Surging Right Now - TipRanks
Alumis (NASDAQ:ALMS) Stock Price Up 6.6% Following Insider Buying Activity - MarketBeat
Alumis' Meteoric Rise To $20 From $5 In Just 60 Days On Plaque Psoriasis Trial Results - RTTNews
Akkaraju of Alumis buys shares worth $9.9 million By Investing.com - Investing.com Nigeria
Alumis (ALMS) Price Target Increased by 79.14% to 36.28 - Nasdaq
Alumis Inc stock hits all-time high at 22.33 USD By Investing.com - Investing.com Nigeria
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Psoriasis Data And Follow On Equity Offering - simplywall.st
Insider Makes Bold Multimillion-Dollar Bet on Alumis Inc. - TipRanks
Insider Buying: Alumis (NASDAQ:ALMS) Director Purchases 588,235 Shares of Stock - MarketBeat
Aug Sectors: Will Alumis Inc stock benefit from automation2025 Performance Recap & Low Drawdown Momentum Trade Ideas - moha.gov.vn
Akkaraju of Alumis buys shares worth $9.9 million - Investing.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Hedge Fund and Insider Trading News: Bill Ackman, Ray Dalio, Warren Buffett, Balyasny Asset Management, Schonfeld Strategic Advisors, Renaissance Technologies, Anson Investments, Limoneira Co (LMNR), Alumis Inc (ALMS), and More - Insider Monkey
Alumis (NASDAQ:ALMS) Reaches New 1-Year High on Insider Buying Activity - MarketBeat
Alumis Inc Stock (ALMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alumis Inc Stock (ALMS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Foresite Labs, LLC | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Foresite Capital Management VI | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Tananbaum James B. | Director |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| AKKARAJU SRINIVAS | Director |
Dec 05 '25 |
Buy |
9.84 |
186,377 |
1,833,760 |
1,265,253 |
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
| AKKARAJU SRINIVAS | Director |
Nov 28 '25 |
Buy |
7.64 |
38,702 |
295,683 |
730,499 |
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):